For Atrial Fibrillation, DOACs Outperform Warfarin in Patients with Reduced Kidney Function.
Where this comes from
- Record sourced from PubMed, PMID 39824643.
- Also identified by DOI 10.3122/jabfm.2024.240155R0.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
At standard doses, direct oral anticoagulants (DOACs) were associated with a reduced risk of systemic embolism and intracranial hemorrhage (ICH) when compared with warfarin, with a greater derived benefit at lower creatinine clearance (CrCl-down to 25 mL/min). Lower doses of DOACs were associated with increased overall mortality without a significant decrease in ICH and incident bleeding when compared with standard dose DOACs and warfarin, across all CrCl down to 25 mL/min.<sup>1</sup>.
Medical subject headings
- Atrial Fibrillation
- Warfarin
- Anticoagulants
- Stroke
- Factor Xa Inhibitors